GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Penwest Pharmaceuticals Co. (PPCO) [hlAlert]

Rating:
Buy PPCO
down 7.16 %

Penwest Pharmaceuticals Co. (PPCO) rated Buy with price target $6 by Pacific Growth Equities

Posted on: Thursday,  Jul 3, 2008  10:25 AM ET by Pacific Growth Equities

Pacific Growth Equities rated Buy Penwest Pharmaceuticals Co. (NASDAQ: PPCO) on 07/03/2008, when the stock price was $2.79.
Since then, Penwest Pharmaceuticals Co. has lost 7.17% as of 11/03/2010's recent price of $2.59.
If you would have followed this Pacific Growth Equities's recommendation on PPCO, you would have lost 7.16% of your investment in 853 days.

Penwest Pharmaceuticals Co. (Penwest) is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. The Company is developing A0001, a coenzyme Q analog drug candidate that it licensed from Edison Pharmaceuticals, Inc. (Edison), for inherited mitochondrial respiratory chain diseases. The Company is also applying its drug delivery technologies and drug formulation expertise to the formulation of product candidates under licensing collaborations, referred to as drug delivery technology collaborations.

The Pacific Growth Equities research department strives to stay ahead of breaking news in some of the fastest moving and most complicated industries on Wall Street. Our research names are affected not only by economic swings but also by specific government regulations, new legislation, and often public opinion. Staying on top of every nuance allows us—and our clients—to lead and not follow. We take pride in providing incremental, value-added insights to the global institutional investment community. Our analysts are experienced in both industry and Wall Street, and are empowered to make the tough calls. Research insights are delivered quickly to the appropriate decision-makers so that important investment opportunities will not be lost. Any research analyst can call an impromptu meeting when news is breaking, to keep the sales force and management abreast of events that could impact the market both from a macro point of view and from one that is stock-specific.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/3/2008 10:25 AM Buy
None
2.79 6.00
as of 12/24/2008
1 Week down  -0.60 %
1 Month up  3.16 %
3 Months down  -11.41 %
1 YTD up  3.82 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy